Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorKuopio University Hospital
About this trial
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
Eligibility criteria
Qualifiers
The patient must sign informed consent to participate in the study.
Patients must be over 18 years of age.
Patients must have histologically confirmed metastatic prostate adenocarcinoma. Histological samples may show neuroendocrine features, but the primary component must be adenocarcinoma.
Patients must have metastatic castration-resistant prostate cancer (mCRPC) that has been treated with at least docetaxel and abiraterone or enzalutamide, or the patients must have declined chemotherapy or be ineligible for docetaxel-based chemotherapy due to contraindications.
Disqualifiers
Patients whose physical condition and cooperation are insufficient to follow the given instructions.
Patients who do not meet the criteria mentioned in the inclusion criteria.
Patients must not have PSMA-negative tumor burden in the liver. The amount of PSMA-negative tumor burden must not exceed the amount of PSMA-positive tumor burden.
Patients with symptomatic untreated spinal cord compression.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Kuopio University Hospital
Lead sponsor
University of Eastern Finland
Collaborator
Source ClinicalTrials.gov